Wanda Christ
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wanda Christ has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Jonas Klingström
Division of Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Linköping University, 581 83 Linköping, Sweden
17 shared publications - Marina García
Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
7 shared publications - Sara Gredmark-Russ
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden
7 shared publications - Kimia T. Maleki
Karolinska Institutet
6 shared publications - Renata Varnaitė
Karolinska Institutet
6 shared publications - Hedvig Glans
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
4 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 24 September 2025
- Published by Springer Nature in Nature
- Vol. 646 (8086) , 945-952
LRP8 is a receptor for tick-borne encephalitis virus
Tick-borne encephalitis virus (TBEV) causes tick-borne encephalitis (TBE), a severe and sometimes life-threatening disease characterized by viral invasion of the central nervous system with symptoms of neuroinflammation1,2. As with other orthoflaviviruses—enveloped, arthropod-borne RNA viruses—host factors required for TBEV entry remain poorly defined. Here we used a genome-scale CRISPR–Cas9-based screen to identify LRP8, an apolipoprotein E and reelin receptor with high expression in the brain, as a TBEV receptor. LRP8 downregulation reduced TBEV infection in human cells, and its overexpression enhanced infection. LRP8 bound directly to the TBEV E glycoprotein and mediated viral attachment and internalization into cells. An LRP8-based soluble decoy blocked infection of human cell lines and neuronal cells and protected mice from lethal TBEV challenge. LRP8’s role as a TBEV receptor has implications for TBEV neuropathogenesis and the development of antiviral countermeasures.
- 24 September 2025
- Published by Springer Nature in Nature
- Vol. 646 (8086) , 945-952
Top Cited PapersOpen AccessLRP8 is a receptor for tick-borne encephalitis virus
Tick-borne encephalitis virus (TBEV) causes tick-borne encephalitis (TBE), a severe and sometimes life-threatening disease characterized by viral invasion of the central nervous system with symptoms of neuroinflammation1,2. As with other orthoflaviviruses—enveloped, arthropod-borne RNA viruses—host factors required for TBEV entry remain poorly defined. Here we used a genome-scale CRISPR–Cas9-based screen to identify LRP8, an apolipoprotein E and reelin receptor with high expression in the brain, as a TBEV receptor. LRP8 downregulation reduced TBEV infection in human cells, and its overexpression enhanced infection. LRP8 bound directly to the TBEV E glycoprotein and mediated viral attachment and internalization into cells. An LRP8-based soluble decoy blocked infection of human cell lines and neuronal cells and protected mice from lethal TBEV challenge. LRP8’s role as a TBEV receptor has implications for TBEV neuropathogenesis and the development of antiviral countermeasures.
- Open Access
- 16 June 2025
- Vol. 2025, 2265813
A Prospective Study of Immune Response After COVID-19 or Vaccination and Correlation Between Avidity Index and Neutralizing Capacity
Background: Serological response is an important aspect of COVID-19, especially for evaluation of vaccine effect and risk of severe infection. The gold standard to assess this is analysis of neutralization capacity, but such assays are not widely available, with antibody levels often used as an approximation of the neutralizing ability. Avidity index is a measure of antibody function and avidity maturation contributes to long-lasting immunity.
- 16 June 2025
- Vol. 2025, 2265813
Open AccessA Prospective Study of Immune Response After COVID-19 or Vaccination and Correlation Between Avidity Index and Neutralizing Capacity
Background: Serological response is an important aspect of COVID-19, especially for evaluation of vaccine effect and risk of severe infection. The gold standard to assess this is analysis of neutralization capacity, but such assays are not widely available, with antibody levels often used as an approximation of the neutralizing ability. Avidity index is a measure of antibody function and avidity maturation contributes to long-lasting immunity.
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Virology
- Vol. 2025 (1)
A Prospective Study of Immune Response After COVID‐19 or Vaccination and Correlation Between Avidity Index and Neutralizing Capacity
Background: Serological response is an important aspect of COVID‐19, especially for evaluation of vaccine effect and risk of severe infection. The gold standard to assess this is analysis of neutralization capacity, but such assays are not widely available, with antibody levels often used as an approximation of the neutralizing ability. Avidity index is a measure of antibody function and avidity maturation contributes to long‐lasting immunity. Objectives: To evaluate if the avidity index gives a better estimation of the neutralizing ability compared with anti‐spike IgG levels and to compare the immune response between infection and vaccination against SARS‐CoV‐2. Study Design: Serum samples from prospectively included patients with either PCR‐confirmed COVID‐19 or COVID‐19‐naïve after vaccination were analyzed for anti‐spike IgG, avidity index, and neutralizing titer at 1, 3, and 6 months after infection or vaccination. Results: A significant correlation between anti‐spike IgG level and neutralization titer was found (Spearman r s = 0.88, p < 0.001), but for the avidity index, the correlation was lower (Spearman r s = 0.62, p < 0.001). Anti‐spike IgG level, avidity index, and neutralization titer were significantly higher in the vaccine cohort. Natural infection failed to yield high‐avidity antibodies. Over time, the antibody levels and neutralization titer declined in both the vaccine and infection cohorts. Conclusion: Anti‐spike IgG levels can be used as an estimation of the neutralizing titer, with the avidity index not contributing to a better estimation. There is a stronger initial immune response after vaccination, compared with natural infection. However, specific antibody levels decline over time, highlighting the importance of vaccine boosters.
- 1 January 2025
- Published by Wiley in Advances in Virology
- Vol. 2025 (1)
Open AccessA Prospective Study of Immune Response After COVID‐19 or Vaccination and Correlation Between Avidity Index and Neutralizing Capacity
Background: Serological response is an important aspect of COVID‐19, especially for evaluation of vaccine effect and risk of severe infection. The gold standard to assess this is analysis of neutralization capacity, but such assays are not widely available, with antibody levels often used as an approximation of the neutralizing ability. Avidity index is a measure of antibody function and avidity maturation contributes to long‐lasting immunity. Objectives: To evaluate if the avidity index gives a better estimation of the neutralizing ability compared with anti‐spike IgG levels and to compare the immune response between infection and vaccination against SARS‐CoV‐2. Study Design: Serum samples from prospectively included patients with either PCR‐confirmed COVID‐19 or COVID‐19‐naïve after vaccination were analyzed for anti‐spike IgG, avidity index, and neutralizing titer at 1, 3, and 6 months after infection or vaccination. Results: A significant correlation between anti‐spike IgG level and neutralization titer was found (Spearman r s = 0.88, p < 0.001), but for the avidity index, the correlation was lower (Spearman r s = 0.62, p < 0.001). Anti‐spike IgG level, avidity index, and neutralization titer were significantly higher in the vaccine cohort. Natural infection failed to yield high‐avidity antibodies. Over time, the antibody levels and neutralization titer declined in both the vaccine and infection cohorts. Conclusion: Anti‐spike IgG levels can be used as an estimation of the neutralizing titer, with the avidity index not contributing to a better estimation. There is a stronger initial immune response after vaccination, compared with natural infection. However, specific antibody levels decline over time, highlighting the importance of vaccine boosters.
- Open Access
IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in hantavirus infected cells and correlate to severity in HFRS
Background: Hantavirus causes hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Strong inflammatory responses and vascular leakage are important hallmarks of these often fatal diseases. The mechanism behind pathogenesis is unknown and no specific treatment is available. IL-6 was recently highlighted as a biomarker for HPS/HFRS severity. IL-6 signaling is complex and context dependent: while classical signaling generally provide protective responses, trans-signaling can cause severe pathogenic responses. This study aims to investigate a potential role for IL-6 trans-signaling in hantavirus pathogenesis. Methods: Effects of IL-6 trans-signaling during in vitro hantavirus infection were assessed using primary human endothelial cells treated with recombinant soluble IL-6 receptor (sIL-6R). Plasma from Puumala orthohantavirus-infected HFRS patients (n=28) were analyzed for IL-6 trans-signaling potential and its associations to severity. Findings: In vitro , sIL-6R treatment of infected cells enhanced IL-6 and CCL2 secretion, upregulated ICAM-1, and affected VE-cadherin leading to a disrupted cell barrier integrity. HFRS patients showed altered plasma levels of sIL-6R and soluble gp130 (sgp130) resulting in an increased sIL-6R/sgp130 ratio suggesting enhanced IL-6 trans-signaling potential. Plasma sgp130 levels negatively correlated with number of interventions and positively with albumin levels. Patients receiving oxygen treatment displayed a higher sIL-6R/sgp130 ratio compared to patients that did not. Interpretation: IL-6 trans-signaling is linked to hantavirus pathogenesis. Targeting IL-6 trans-signaling might provide a therapeutic strategy for treatment of HPS and severe HFRS. Research in context: Evidence before this study: IL-6 have dual effects, it provides important antiviral responses but can also cause severe pathogenesis. IL-6 mediated effects are activated by two different mechanisms, classical signaling and trans-signaling. IL-6 trans-signaling have recently been shown to be responsible for IL-6 mediated pathogenesis. Endothelial cells lack membrane-bound IL-6 receptor and only respond to IL-6 trans-signaling. Orthohantaviruses cause hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS; also called hantavirus cardiopulmonary syndrome (HCPS)), acute severe zoonotic diseases with high fatality rates for which specific treatments and vaccines are lacking. Deregulated vascular permeability and inflammation are hallmarks of HPS and severe HFRS. However, the mechanisms underlying hantavirus disease are unknown, hampering the development of treatments. Orthohantaviruses primarily infect endothelial cells. Previous studies have demonstrated a correlation between elevated IL-6 levels and increased severity of HPS and HFRS. Whether this link is causal, and if so the mechanisms behind it, has not been determined. Added value of this study: This study demonstrates that hantavirus-infected endothelial cells produce large amounts of IL-6, and are highly sensitive to IL-6 trans-signaling mechanisms. Together this strongly amplifies the IL-6 production and disrupt the endothelial cell barrier causing severe fluid leakage. When analyzing a potential role for IL-6 trans-signaling in patients, we observed increased systemic IL-6 trans-signaling potential, and that this was linked to severity, in Puumala virus-infected HFRS patients. Implications of all the available evidence: These data suggest the two hallmarks of HPS and HFRS; increased vascular permeability and strong inflammation, is linked via hantavirus-induced endothelial cell IL-6 production and IL-6 trans-signaling effects. Treatment targeting IL-6 trans-signaling might provide a therapeutic strategy for HPS and severe HFRS.
Open AccessIL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in hantavirus infected cells and correlate to severity in HFRS
Background: Hantavirus causes hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Strong inflammatory responses and vascular leakage are important hallmarks of these often fatal diseases. The mechanism behind pathogenesis is unknown and no specific treatment is available. IL-6 was recently highlighted as a biomarker for HPS/HFRS severity. IL-6 signaling is complex and context dependent: while classical signaling generally provide protective responses, trans-signaling can cause severe pathogenic responses. This study aims to investigate a potential role for IL-6 trans-signaling in hantavirus pathogenesis. Methods: Effects of IL-6 trans-signaling during in vitro hantavirus infection were assessed using primary human endothelial cells treated with recombinant soluble IL-6 receptor (sIL-6R). Plasma from Puumala orthohantavirus-infected HFRS patients (n=28) were analyzed for IL-6 trans-signaling potential and its associations to severity. Findings: In vitro , sIL-6R treatment of infected cells enhanced IL-6 and CCL2 secretion, upregulated ICAM-1, and affected VE-cadherin leading to a disrupted cell barrier integrity. HFRS patients showed altered plasma levels of sIL-6R and soluble gp130 (sgp130) resulting in an increased sIL-6R/sgp130 ratio suggesting enhanced IL-6 trans-signaling potential. Plasma sgp130 levels negatively correlated with number of interventions and positively with albumin levels. Patients receiving oxygen treatment displayed a higher sIL-6R/sgp130 ratio compared to patients that did not. Interpretation: IL-6 trans-signaling is linked to hantavirus pathogenesis. Targeting IL-6 trans-signaling might provide a therapeutic strategy for treatment of HPS and severe HFRS. Research in context: Evidence before this study: IL-6 have dual effects, it provides important antiviral responses but can also cause severe pathogenesis. IL-6 mediated effects are activated by two different mechanisms, classical signaling and trans-signaling. IL-6 trans-signaling have recently been shown to be responsible for IL-6 mediated pathogenesis. Endothelial cells lack membrane-bound IL-6 receptor and only respond to IL-6 trans-signaling. Orthohantaviruses cause hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS; also called hantavirus cardiopulmonary syndrome (HCPS)), acute severe zoonotic diseases with high fatality rates for which specific treatments and vaccines are lacking. Deregulated vascular permeability and inflammation are hallmarks of HPS and severe HFRS. However, the mechanisms underlying hantavirus disease are unknown, hampering the development of treatments. Orthohantaviruses primarily infect endothelial cells. Previous studies have demonstrated a correlation between elevated IL-6 levels and increased severity of HPS and HFRS. Whether this link is causal, and if so the mechanisms behind it, has not been determined. Added value of this study: This study demonstrates that hantavirus-infected endothelial cells produce large amounts of IL-6, and are highly sensitive to IL-6 trans-signaling mechanisms. Together this strongly amplifies the IL-6 production and disrupt the endothelial cell barrier causing severe fluid leakage. When analyzing a potential role for IL-6 trans-signaling in patients, we observed increased systemic IL-6 trans-signaling potential, and that this was linked to severity, in Puumala virus-infected HFRS patients. Implications of all the available evidence: These data suggest the two hallmarks of HPS and HFRS; increased vascular permeability and strong inflammation, is linked via hantavirus-induced endothelial cell IL-6 production and IL-6 trans-signaling effects. Treatment targeting IL-6 trans-signaling might provide a therapeutic strategy for HPS and severe HFRS.
- Open Access
- 22 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Comprehensive proteomics and meta-analysis of COVID-19 host response
COVID-19 is characterised by systemic immunological perturbations in the human body, which can lead to multi-organ damage. Many of these processes are considered to be mediated by the blood. Therefore, to better understand the systemic host response to SARS-CoV-2 infection, we performed systematic analyses of the circulating, soluble proteins in the blood through global proteomics by mass-spectrometry (MS) proteomics. Here, we show that a large part of the soluble blood proteome is altered in COVID-19, among them elevated levels of interferon-induced and proteasomal proteins. Some proteins that have alternating levels in human cells after a SARS-CoV-2 infection in vitro and in different organs of COVID-19 patients are deregulated in the blood, suggesting shared infection-related changes.The availability of different public proteomic resources on soluble blood proteome alterations leaves uncertainty about the change of a given protein during COVID-19. Hence, we performed a systematic review and meta-analysis of MS global proteomics studies of soluble blood proteomes, including up to 1706 individuals (1039 COVID-19 patients), to provide concluding estimates for the alteration of 1517 soluble blood proteins in COVID-19. Finally, based on the meta-analysis we developed CoViMAPP, an open-access resource for effect sizes of alterations and diagnostic potential of soluble blood proteins in COVID-19, which is publicly available for the research, clinical, and academic community.
- 22 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Open AccessComprehensive proteomics and meta-analysis of COVID-19 host response
COVID-19 is characterised by systemic immunological perturbations in the human body, which can lead to multi-organ damage. Many of these processes are considered to be mediated by the blood. Therefore, to better understand the systemic host response to SARS-CoV-2 infection, we performed systematic analyses of the circulating, soluble proteins in the blood through global proteomics by mass-spectrometry (MS) proteomics. Here, we show that a large part of the soluble blood proteome is altered in COVID-19, among them elevated levels of interferon-induced and proteasomal proteins. Some proteins that have alternating levels in human cells after a SARS-CoV-2 infection in vitro and in different organs of COVID-19 patients are deregulated in the blood, suggesting shared infection-related changes.The availability of different public proteomic resources on soluble blood proteome alterations leaves uncertainty about the change of a given protein during COVID-19. Hence, we performed a systematic review and meta-analysis of MS global proteomics studies of soluble blood proteomes, including up to 1706 individuals (1039 COVID-19 patients), to provide concluding estimates for the alteration of 1517 soluble blood proteins in COVID-19. Finally, based on the meta-analysis we developed CoViMAPP, an open-access resource for effect sizes of alterations and diagnostic potential of soluble blood proteins in COVID-19, which is publicly available for the research, clinical, and academic community.
- Open Access
- 15 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19
Effective humoral immune responses require well-orchestrated B and T follicular helper (Tfh) cell interactions. Whether these interactions are impaired and associated with COVID-19 disease severity is unclear. Here, longitudinal blood samples across COVID-19 disease severity are analysed. We find that during acute infection SARS-CoV-2-specific circulating Tfh (cTfh) cells expand with disease severity. SARS-CoV-2-specific cTfh cell frequencies correlate with plasmablast frequencies and SARS-CoV-2 antibody titers, avidity and neutralization. Furthermore, cTfh cells but not other memory CD4 T cells, from severe patients better induce plasmablast differentiation and antibody production compared to cTfh cells from mild patients. However, virus-specific cTfh cell development is delayed in patients that display or later develop severe disease compared to those with mild disease, which correlates with delayed induction of high-avidity neutralizing antibodies. Our study suggests that impaired generation of functional virus-specific cTfh cells delays high-quality antibody production at an early stage, potentially enabling progression to severe disease.
- 15 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessDelayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19
Effective humoral immune responses require well-orchestrated B and T follicular helper (Tfh) cell interactions. Whether these interactions are impaired and associated with COVID-19 disease severity is unclear. Here, longitudinal blood samples across COVID-19 disease severity are analysed. We find that during acute infection SARS-CoV-2-specific circulating Tfh (cTfh) cells expand with disease severity. SARS-CoV-2-specific cTfh cell frequencies correlate with plasmablast frequencies and SARS-CoV-2 antibody titers, avidity and neutralization. Furthermore, cTfh cells but not other memory CD4 T cells, from severe patients better induce plasmablast differentiation and antibody production compared to cTfh cells from mild patients. However, virus-specific cTfh cell development is delayed in patients that display or later develop severe disease compared to those with mild disease, which correlates with delayed induction of high-avidity neutralizing antibodies. Our study suggests that impaired generation of functional virus-specific cTfh cells delays high-quality antibody production at an early stage, potentially enabling progression to severe disease.
- Open Access
- 22 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-10
Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
Vaccination offers protection against severe COVID-19 caused by SARS-CoV-2 omicron but is less effective against infection. Characteristics such as serum antibody titer correlation to protection, viral abundance and clearance of omicron infection in vaccinated individuals are scarce. We present a 4-week twice-weekly SARS-CoV-2 qPCR screening in 368 triple vaccinated healthcare workers. Spike-specific IgG levels, neutralization titers and mucosal spike-specific IgA-levels were determined at study start and qPCR-positive participants were sampled repeatedly for two weeks. 81 (cumulative incidence 22%) BA.1, BA.1.1 and BA.2 infections were detected. High serum antibody titers are shown to be protective against infection (p < 0.01), linked to reduced viral load (p < 0.01) and time to viral clearance (p < 0.05). Pre-omicron SARS-CoV-2 infection is independently associated to increased protection against omicron, largely mediated by mucosal spike specific IgA responses (nested models lr test p = 0.02 and 0.008). Only 10% of infected participants remain asymptomatic through the course of their infection. We demonstrate that high levels of vaccine-induced spike-specific WT antibodies are linked to increased protection against infection and to reduced viral load if infected, and suggest that the additional protection offered by pre-omicron SARS-CoV-2 infection largely is mediated by mucosal spike-specific IgA.
- 22 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-10
Open AccessCorrelates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
Vaccination offers protection against severe COVID-19 caused by SARS-CoV-2 omicron but is less effective against infection. Characteristics such as serum antibody titer correlation to protection, viral abundance and clearance of omicron infection in vaccinated individuals are scarce. We present a 4-week twice-weekly SARS-CoV-2 qPCR screening in 368 triple vaccinated healthcare workers. Spike-specific IgG levels, neutralization titers and mucosal spike-specific IgA-levels were determined at study start and qPCR-positive participants were sampled repeatedly for two weeks. 81 (cumulative incidence 22%) BA.1, BA.1.1 and BA.2 infections were detected. High serum antibody titers are shown to be protective against infection (p < 0.01), linked to reduced viral load (p < 0.01) and time to viral clearance (p < 0.05). Pre-omicron SARS-CoV-2 infection is independently associated to increased protection against omicron, largely mediated by mucosal spike specific IgA responses (nested models lr test p = 0.02 and 0.008). Only 10% of infected participants remain asymptomatic through the course of their infection. We demonstrate that high levels of vaccine-induced spike-specific WT antibodies are linked to increased protection against infection and to reduced viral load if infected, and suggest that the additional protection offered by pre-omicron SARS-CoV-2 infection largely is mediated by mucosal spike-specific IgA.
- Open Access
- 4 March 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 375 (6584) , 1041-1047
Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC) responses in individuals who received either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous messenger RNA (mRNA) booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared with that of homologous ChAdOx1 boosting. Specificity mapping of circulating B cells revealed that mRNA-1273 boost immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273–boosted participants displayed overall higher binding affinities and increased breadth of reactivity against VOCs relative to those isolated from ChAdOx1-boosted individuals. Overall, the results provide molecular insight into the enhanced quality of the B cell response induced after heterologous mRNA booster vaccination.
- 4 March 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 375 (6584) , 1041-1047
Open AccessBroad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC) responses in individuals who received either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous messenger RNA (mRNA) booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared with that of homologous ChAdOx1 boosting. Specificity mapping of circulating B cells revealed that mRNA-1273 boost immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273–boosted participants displayed overall higher binding affinities and increased breadth of reactivity against VOCs relative to those isolated from ChAdOx1-boosted individuals. Overall, the results provide molecular insight into the enhanced quality of the B cell response induced after heterologous mRNA booster vaccination.
- Open Access
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primary vaccination with homologous adeno-vectored ChAdOx1 nCoV-19 vaccine (ChAd) or heterologous ChAd/BNT162b2 mRNA vaccine (BNT), anti-spike-IgG and SARS-CoV-2 VOC-neutralizing antibody responses were measured in 354 healthcare workers (HCW) at 2 weeks, 3 months, 5 months and 6 months after the second vaccine dose. T-cell responses were investigated using a whole blood interferon gamma (IFN-γ) release assay 2 weeks and 3 months post second vaccine dose. Two hundred and ten HCW immunized with homologous BNT were enrolled for comparison of antibody responses. In study participants naïve to SARS-CoV-2 prior to vaccination, heterologous ChAd/BNT resulted in 6-fold higher peak anti-spike IgG antibody titers compared to homologous ChAd vaccination. The half-life of antibody titers was 3.1 months (95% CI 2.8–3.6) following homologous ChAd vaccination and 1.9 months (95% CI 1.7–2.1) after heterologous vaccination, reducing the GMT difference between the groups to 3-fold 6 months post vaccination. Peak T-cell responses were stronger in ChAd/BNT vaccinees, but no significant difference was observed 3 months post vaccination. SARS-CoV-2 infection prior to vaccination resulted in substantially higher peak GMTs and IFN-γ levels and enhanced SARS-CoV-2 specific antibody and T cell responses over time. Heterologous primary SARS-CoV-2 immunization with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.
Open AccessDuration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primary vaccination with homologous adeno-vectored ChAdOx1 nCoV-19 vaccine (ChAd) or heterologous ChAd/BNT162b2 mRNA vaccine (BNT), anti-spike-IgG and SARS-CoV-2 VOC-neutralizing antibody responses were measured in 354 healthcare workers (HCW) at 2 weeks, 3 months, 5 months and 6 months after the second vaccine dose. T-cell responses were investigated using a whole blood interferon gamma (IFN-γ) release assay 2 weeks and 3 months post second vaccine dose. Two hundred and ten HCW immunized with homologous BNT were enrolled for comparison of antibody responses. In study participants naïve to SARS-CoV-2 prior to vaccination, heterologous ChAd/BNT resulted in 6-fold higher peak anti-spike IgG antibody titers compared to homologous ChAd vaccination. The half-life of antibody titers was 3.1 months (95% CI 2.8–3.6) following homologous ChAd vaccination and 1.9 months (95% CI 1.7–2.1) after heterologous vaccination, reducing the GMT difference between the groups to 3-fold 6 months post vaccination. Peak T-cell responses were stronger in ChAd/BNT vaccinees, but no significant difference was observed 3 months post vaccination. SARS-CoV-2 infection prior to vaccination resulted in substantially higher peak GMTs and IFN-γ levels and enhanced SARS-CoV-2 specific antibody and T cell responses over time. Heterologous primary SARS-CoV-2 immunization with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.
- Open Access
- 21 February 2022
- Published by Elsevier in Cell Reports
- Vol. 38 (10) , 110503
SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells
- 21 February 2022
- Published by Elsevier in Cell Reports
- Vol. 38 (10) , 110503
Open AccessSARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells